LIVE
BREAKING LIVE

The news moving markets, right now

From international newswires in real time. For every story the News Impact AI agent estimates the market impact and flags the assets to watch, with the story’s impact on each: positive, negative or neutral.

STORIES TODAY
15
via finance.yahoo.comBusiness & Companies

Novartis gains FDA approval for Cosentyx in PMR and ADC deal with OBI Pharma

FROM THE WIRE · FINANCE.YAHOO.COM

Novartis (SWX:NOVN) reported US FDA approval of Cosentyx as the first anti IL 17 biologic for polymyalgia rheumatica. The new Cosentyx indication targets patients with polymyalgia rheumatica who currently rely heavily on long term steroid treatment. Novartis agreed a global…

Read at the source ↗
MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishRegulatory approval and a new licensing deal at a large pharma group are relevant for the stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
  1. 01The FDA approved Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica.
  2. 02Novartis signed a global antibody drug conjugate licensing and development deal with OBI Pharma.
  3. 03The new use targets patients who rely heavily on long-term steroid treatment.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets

ALL BREAKING TODAY

Breaking live stories come from third-party newswires via feed; headline and summary belong to the stated source. Impact analysis: UCapital AI · News Impact.

AI use policy. UCapital AI supports the newsroom with news analysis, summaries, market reactions, translations and the generation of cards and charts. AI-generated or AI-assisted content is labelled in the byline (AI Desk, a named AI profile marked «AI», or joint byline) and is reviewed by editors before publication. News received via API feeds from third-party providers is attributed to the original source. AI can make mistakes: report any inaccuracies to the newsroom. Users’ personal data is not used to train the models.